PFS according to BCR-ABL transcript levels at 6 months. Among patients receiving dasatinib, 69%, 19%, and 11% achieved BCR-ABL transcript levels ≤1%, >1% to 10%, and >10% at 6 months, respectively. Among patients receiving imatinib, the percentages were 49%, 34%, and 17%, respectively. Patients with response data at 6 months and outcome data after 6 months were included in the analysis.